Advanced Nasopharyngeal Carcinoma
Conditions
Brief summary
Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and lymph node metastasis, quality of life improvement rate, etc.
Detailed description
1\. The main purpose: Whether the GP program can improve the efficiency of patients with nasopharyngeal carcinoma, especially overall survival (OS), in the TPF program. 2. Secondary purpose: To compare the progression-free survival (PFS) local failure-free survival (LR-FFS), the short-term remission rate of the tumor, the adverse chemotherapy response, and the treatment compliance Sex, as well as quality of life. 3. Significance of the research project Nasopharyngeal carcinoma is sensitive to radiotherapy and chemotherapy. Platinum-based chemotherapy is used in the treatment of distant metastasis and metastasis. It can effectively alleviate local symptoms and reduce local symptoms. The tumor volume thereby reduces the high dose area of the target area. Primary lesions and lymphatic drainage area radiotherapy can reduce tumor burden, relieve symptoms, and improve quality of life.
Interventions
DRUGGP+IMRT
Gemcitabine 1000 mg/m2 intravenously, d1&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\ 28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
DRUGTPF+IMRT
Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\ d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\ d521\ 28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
Sponsors
Guiyang Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. The pathological type is non-keratinized cancer (according to the pathological classification of the World Health Organization, WHO). 2. The stage is TxNxM1 (according to the eighth edition of the AJCC staging standard) (Appendix I). 3. There is evidence of distant transfer (M1). 4. functional status: Karnofsky scale (KPS) \> 70 (Appendix II). 5. normal bone marrow function: white blood cell count \> 4 × 109 / L, hemoglobin \> 90g / L and platelet count \> 100 × 109 / L. 6. normal liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \<1.5 times the upper limit of normal (ULN), and alkaline phosphatase (alkaline phosphatase, ALP) \< 2.5 x ULN and bilirubin \< ULN. 7. normal renal function: creatinine clearance (creatinine clearance) \> 60 ml / min. 8. The patient must be informed of the basic content of the study and sign an informed consent form. \-
Exclusion criteria
1. the pathological type is WHO keratinized squamous cell carcinoma or basal squamous cell carcinoma. 2. age \> 65 years old or \< 18 years old. 3. a history of malignant tumors, except for adequately treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ. 4. Women during pregnancy or lactation (pregnancy tests should be considered for women of childbearing age; effective contraception should be emphasized during treatment). 5. has received radiation therapy (if it is non-melanoma skin cancer and the previous lesion is placed Except for the target area of treatment. 6. primary lesions and cervical metastases have received chemotherapy or surgery (except for diagnostic treatment). 7. accompanied by other serious diseases, may bring greater risk or affect the compliance of the test. For example: unstable heart disease, kidney disease, chronic hepatitis, uncontrolled diabetes (fasting blood glucose \> 1.5 x ULN), and mental illness. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progress-free survival(PFS) | 3 years | Progress-free survival(year) is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival(OS) | 3 years | The OS(year) was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up. |
| Locoregional failure-free survival(LRFS) | 3 years | The LRFS(year) is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit. |
| Distant metastasis-free survival(DMFS) | 3 years | The DMFS(year) is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit. |
| Overall response rate | 3 years | Tumour response(CR/PR/SD/PD) was classified according to RECIST v1.1 |
| Incidence of acute and late toxicity | 3 years | Incidence of acute toxicity（Grade1/2/3/4） is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme |
Countries
China
Contacts
Primary ContactFeng Jin, Bachelor
Backup ContactJinhua Long, Master
Outcome results
None listed